MedTrace Logo

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

NCT06370039 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-07-02

No results posted yet for this study

Summary

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.

Conditions

Interventions

DRUG

INV-102

INV-102 Ophthalmic Solution

DRUG

Vehicle

Vehicle Ophthalmic Solution

Sponsors & Collaborators

  • Invirsa, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Shalwitz, MD · Invirsa, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-27
Primary Completion
2024-07-03
Completion
2024-07-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06370039 on ClinicalTrials.gov